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Contact system activation in human sepsis - 47 kD HK, a marker
of sepsis severity?
Abstract
AIM: This pilot study seeks to determine whether contact system activation (CSA) occurs in human
sepsis patients and to characterise blood levels of the 47kD light chain of high-molecular weight
kininogen (47kD HK). METHODS: Six consecutive patients with clinical suspicion of sepsis were
evaluated on days 1, 2, 3 and 6-8 for 47kD HK blood levels expressed in U/ml of whole blood and as
percent of total HK. 47kD HK was measured in whole blood by quantitative immunoblot analysis.
RESULTS: On study day 1 or 2, analysis of 47kD HK in U/ml of whole blood identified CSA in 3/6
patients.When 47kD HK levels were expressed as percent of total HK, 4/6 patients were identified with
CSA before day 3. The degree of CSA as assayed by the presence of 47kD HK correlated with the
severity of the systemic inflammatory syndrome (SIRS), i.e. mean CSA increased progressively from
basal levels in healthy controls (0.08 U/ml or 10.4%) to patients without SIRS (0.10 U/ml or 15.1%), to
patients with sepsis (0.12 U/ml or 15.0%), and finally to patients in a combined category of severe
sepsis and septic shock (0.13 U/ml or 17.4%). CONCLUSION: CSA, defined by increased 47kD HK,
occurred early on in the course of sepsis in a subset of sepsis patients. 47kD HK levels, an indicator of
bradykinin release, correlated with sepsis severity. Future larger studies will need to evaluate the role of
47kD HK as a biomarker for both prognosis and treatment response in human sepsis.
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Aim: This pilot study seeks to determine
whether contact system activation (CSA) occurs
in human sepsis patients and to characterise blood
levels of the 47kD light chain of high-molecular
weight kininogen (47kD HK).
Methods: Six consecutive patients with clinical
suspicion of sepsis were evaluated on days 1, 2, 3
and 6–8 for 47kD HK blood levels expressed in
U/ml of whole blood and as percent of total HK.
47kD HK was measured in whole blood by quan-
titative immunoblot analysis.
Results: On study day 1 or 2, analysis of 47kD
HK in U/ml of whole blood identiﬁed CSA in 3/6
patients.When 47kDHK levels were expressed as
percent of total HK, 4/6 patients were identiﬁed
with CSA before day 3. The degree of CSA as as-
sayed by the presence of 47kD HK correlated
with the severity of the systemic inﬂammatory
syndrome (SIRS), i.e. mean CSA increased pro-
gressively from basal levels in healthy controls
(0.08 U/ml or 10.4%) to patients without SIRS
(0.10 U/ml or 15.1%), to patients with sepsis
(0.12 U/ml or 15.0%), and ﬁnally to patients in a
combined category of severe sepsis and septic
shock (0.13 U/ml or 17.4%).
Conclusion: CSA, deﬁned by increased 47kD
HK, occurred early on in the course of sepsis in a
subset of sepsis patients. 47kD HK levels, an indi-
cator of bradykinin release, correlated with sepsis
severity. Future larger studies will need to evalu-
ate the role of 47kD HK as a biomarker for both
prognosis and treatment response in human sep-
sis.
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Sepsis is a clinico-pathological syndrome aris-
ing from infection and is deﬁned by the presence
of a systemic inﬂammatory process called sys-
temic inﬂammatory response syndrome or SIRS.
SIRS may result from infectious (i.e. sepsis) or
non-infectious causes. SIRS and sepsis can there-
fore be seen as overlapping entities [1]. Prospec-
tive analysis of 3708 patients with SIRS and sepsis
has shown that there is a clinical progression from
SIRS to sepsis, to severe sepsis, and septic shock.
28-day mortality increases from 7% to 16%, to
20% and 46% respectively [2].
The systems of coagulation and inﬂammation
interact in many ways [3]. On the hypothesis that
one can alter the outcome of sepsis, i.e. reduce
sepsis-related mortality by inﬂuencing coagula-
tion parameters, the effects of drugs that alter the
coagulation system have been studied. To date ac-
tivated protein C is the only coagulation inhibitor
known to improve survival in sepsis patients.
Other studies involving factors such as tissue fac-
tor pathway inhibitor (TFPI), antithrombin III
(ATIII) or C1 inhibitor (C1Inh) have so far failed
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to reduce mortality in human sepsis or were not
sufﬁciently powered to address the issue [4–9].
The search for disease markers allowing identiﬁ-
cation of high-risk subpopulations of patients
likely to beneﬁt most from targeted therapeutic
strategies is ongoing.
Bradykinin, a vasoactive peptide which medi-
ates inﬂammatory signs and sepsis-induced hy-
potension, is generated in vivo by a three-step se-
quential cleavage from a 120kD precursor mole-
cule, high molecular weight kininogen (HK; see
ﬁgure 1) [10–15]. Plasma kallikrein is the serine
protease responsible for endovascular HK cleav-
age [16]. Direct measurement of bradykinin is la-
borious and prone to preanalytical artifacts due to
the very short half-life of 30–50 seconds and basal
plasma concentration in the pmol/l range [17–
21]. We therefore designed an assay measuring
the cleaved 47kD band of HK with a long half-life
as a direct indicator of contact system activation
(CSA) and an indirect indicator of bradykinin re-
lease (see Figure 1).
We hypothesise that contact system activa-
tion occurs early on in the course of sepsis and
hence may be a candidate marker of clinical rele-
vance. A quantitative assay for high molecular
weight kininogen cleavage was designed to study
contact system activation. We characterised this
test by studying the evolution of test results over
time in six patients with suspected sepsis and
compared these results with those of six healthy
controls. Finally, we investigated whether there is
a correlation between the severity of the inﬂam-
matory syndrome and the severity of contact sys-
tem activation.
Figure 1
High-molecular weight kininogen cleavage. Circulating Hk is
cleaved by plasma kallikrein in three sequential steps (see 1,
2 and 3 in panel A).The first cleavage generates 63kd heavy
chain and 61kd light chain.The next cleavage liberates the
polypeptide bradykinin from the heavy chain. Finally, the
third cleavage generates 47kd light chain. Using a poly-
clonal rabbit antiserum directed against 47kd light chain our
assay detects three bands (depicted in gray): 120kd, 61kd
and 47kd. 61kd band is almost undetectable on the im-
munoblots due to increased electrophoretic mobility and
short plasma half-life (see Material and Methods).
Panel B shows an immunoblot used to generate a standard
curve, and immunoblots of a control sample (Con) as well as
a sepsis sample (Pt). For the standard curves Hk deficient
plasma (Hk-) was spiked with normal human plasma to con-
tain the amounts of Hk as indicated (lane 1: only Hk- plasma
= 0%, lane 2: Hk-:NHP = 1:50 or 2%, lane 3 Hk-: NHP = 1:10
or 10%, etc). Whereas 1 μl of plasma was applied per lane
for standard curves, only 0.4 μl of whole blood was added
for test samples. lane 10 shows three molecular weight
(MW) markers at 112, 84 and 52kd.
Patients and methods
Patients
Patients were recruited from the internal medicine
ward, the medical intensive care units (ICU) or the surgi-
cal ICU on the basis of clinical suspicion of sepsis of re-
cent onset on day 0 of the study. The inclusion criterion
was the presence of at least two SIRS deﬁning criteria (see
below) on day 1. Seven consecutive patients were en-
rolled. One patient who died on day 2 was excluded from
the study. Patient characteristics were as follows (patient
number: sex, age, (colour used in ﬁgures): reason for
transfer to ICU and comorbidities): 1: female, 71, (pur-
ple): fever – valvular heart disease (mechanical mitral
valve and severe aortic stenosis); 2: male: 77, (blue)
pseudomonas sepsis 8 days after aortic valve replacement
– valvular heart disease (mechanical aortic valve), ulcera-
tive proctitis, peripheral artery disease; 3: female, 24,
(green): fever – haemophagocytic syndrome; 4: female,
54, (yellow): aspiration pneumonia acquired during gen-
eralised epileptic attack – pituitary insufﬁciency after re-
section of a prolactinoma; 5: male, 57, orange: sigma per-
foration – alcohol abuse, chronic renal failure and recur-
rent gout; 6 male, 44, red: resection of small intestine –
comorbidities not speciﬁed. Six healthy volunteers, 3 fe-
males and 3 males, with ages ranging from 27–47 years
(mean: 37 years) served as controls.
Study protocol
Patients had blood drawn on 4 occasions on days 1,
2, 3 and 6–8. Contact system activation testing was per-
formed on all occasions. Patients’ clinical status pertain-
ing to sepsis was ascertained for each of the 4 study days
on the basis of information documented in the patient
charts.
The American College of Chest Physicians/Society
of Critical Care Medicine Consensus Conference deﬁni-
tions of sepsis and related disorders were used [22]. In
brief, 4 SIRS deﬁning criteria were applied: (i) body tem-
perature <36 or >38 ˚C, (ii) heart rate >90 beats/minute,
A
B
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(iii) tachypnoea with respiratory rate >20/minute or hy-
perventilation with PaCo2<32 Torr (4.3 kPa), and (iv) alter-
ation of white blood count <4 or >12 G/l or the presence
of >10% immature neutrophils (bands). SIRS was deﬁned
by the presence of two or more of the above criteria. Sep-
sis was deﬁned as SIRS due to infection. Severe sepsis was
deﬁned as sepsis associated with organ dysfunction, hy-
poperfusion or hypotension. Septic shock was deﬁned as
a subcategory of severe sepsis characterised by persistent
hypotension unresponsive to adequate ﬂuid resuscitation.
Internal review and patient consent
This study protocol was reviewed and approved by
the Ethical Committee of the University of Berne and
the patients’ administration department of the University
Hospital in Berne. Doctors involved in the direct care of
the patients obtained informed consent from patients or
their families.
Contact system activation assay
A quantitative immunoblotting method for high
molecular weight kininogen was developed on the basis
of previously established methods [23]. Subjects’ whole
blood (WB) was diluted 1:50 in 0.01 M Tris, 0.14 M
sodium chloride, pH 7.4 containing 1 mg/ml bovine
serum albumin and 100 mg/ml soybean trypsin inhibitor
(SBTI). 20 μl of diluted WB were added to 30 ml sample
buffer containing 10% sodium dodecyl sulfate (SDS) and
immediately denatured by heating to 100 °C for 5 min-
utes in a waterbath. Whole blood was used instead of
plasma to minimise handling time and prevent preanalyt-
ical sample degradation. All samples were denatured
within 20 minutes of the blood draw.
Pretest variables were tested in preliminary experi-
ments. Citrate proved to be the optimal anticoagulant as
heparinised samples showed less reproducibility of results
after storage. Storage of denatured samples at room tem-
perature was superior to freezing/defrosting, which in-
duced excessive sample precipitation. Heating the sam-
ples to 100 °C for 5 min. in a waterbath resolubilised
small precipitates which formed in some samples and
permitted sample loading without losses due to non-
entry into the stacking gel. Results of immunoblots pro-
duced using fresh samples and samples stored for 8 days
under these conditions were highly reproducible (data
not shown).
SDS PAGE was performed using a standard discon-
tinuous buffer system [24]. Prior to electrophoresis sam-
ples were reduced with dithio-D-L-threitol (DTT) and
alkylated with iodoacetamide (IAA). Gels contained 10%
of acrylamide (wt/vol). Bisacrylamide was added to make
up 2.6% of total monomer. Four gels with 12 lanes each
were run in parallel overnight, permitting evaluation of
2 subjects in one session
Two separate standard curves were established for
uncleaved and cleaved (47kD band) HK (see ﬁgure 1B).
For uncleaved HK (120kD band) a standard curve was
produced using the dilutions of non-activated normal
human plasma (NHP) supplemented in HK-deﬁcient
plasma to assure equal total plasma content. A similar di-
lution scheme was applied to generate a standard curve
for the 47kD cleavage product of HK. For this purpose
NHP was activated by exposure to dextran sulphate (ﬁnal
concentration: 1.25 mg/ml) for 180 min. before being di-
luted.
Negative controls (1 ml plasma deﬁcient in HK, HK)
were run on each gel in lane 1; lane 12 was used for
prestained molecular weight standards (BioRad, Her-
cules, Ca; 161–0305). For all patient/control samples the
equivalent of 0.4 ml of whole blood was applied per lane.
Internal controls (0.5 or 1.0 ml NHP) were included on
each gel to assure comparability of gels that were run in
parallel.
The immunoblotting technique has been described
previously [23]. HK cleavage was analysed using a rabbit
polyclonal antibody directed against reduced and alky-
lated 47kD light chain of HK (see ﬁgure 1).
Autoradiographs of the immunoblots were scanned
using a personal laser densitometer (Molecular Dynam-
ics, Sunnyvale, CA) and commercial software (MD Image
Quant, version 3.3) [25]. Calibration curves were gener-
ated from the data using Table Curve 2D for Windows
(Jandel Scientiﬁc Software, San Rafael, CA, version 3)
and a transition function [logistic dose response curve: y
= a/(1+(x/b)c].
Normal values were established in six healthy volun-
teers based on 4 blood draws each. These 24 values were
distributed normally. Figure 1 schematically illustrates
HK cleavage (1A) and a normal vs. a sepsis sample (1B).
The antibody detects 120kD, 61kD and 47kD forms
of HK. The 61kD fragment has an increased elec-
trophoretic mobility resulting in partial migration
through the nitrocellulose membrane (data not shown).
This issue and the probable short half-life of the frag-
ment led to the very low levels that we detected for this
fragment.We determined absolute concentrations (U/ml
of whole blood) of each of these bands using two differ-
ent standard curves and a band scanning procedure.
Based on the absolute concentrations of each fragment,
we then calculated the relative concentrations in % of
total HK. For this analysis total HK (100%) was deter-
mined as the sum of uncleaved HK + 61kD HK + 47kD
HK. We deﬁned contact system activation as any result,
for either absolute concentration (U/ml) or for relative
concentration (%), that falls outside the normal range de-
ﬁned by the mean +/- t x SD (t for n = 6 or ﬁve degrees of
freedom = 2.57).
To assure reproducibility, runs with 4 gels were elec-
trophoresed in parallel, blotted in parallel and their au-
toradiographs were exposed in parallel. On the basis of
the internal controls on each gel the intra-run coefﬁcient
of variability (CV) was calculated: mean CV 8.0%, me-
dian CV 7.3%, range 1.6–15.4%. The inter-run CV
could not be calculated as no calibrated source of puriﬁed
HK (uncleaved and cleaved) was available to us.
Coagulation and blood chemistry studies
Coagulation studies such as prothrombin time,
aPTT, thrombin time, reptilase time, ethanol gelation
assay, ﬁbrinogen concentration, clotting activities for vi-
tamin K-dependent coagulation factors (FII, FVII, FX),
for FV and for contact factors (FXII, FXI, HK and PK) as
well as C-reactive protein and creatinine levels were de-
termined according to standardised procedures [25, 26].
Statistical analyses
Sigma Plot for Windows 9.0 (Jandel Scientiﬁc) was
used to perform the statistical calculations.MannWhitney
rank sums test was used to evaluate the data in table 2. For
Figures 2 and 3 standard deviations of the control popu-
lation were calculated using a two-stage sampling ap-
proach [27].
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Clinical course of SIRS/sepsis
Four of the six patients had blood culture-
positive sepsis. In retrospect, in three patients
these cultures turned positive on day 0 of the
study (patients 1 (purple), 2 (blue) and 3 (green)
with Streptoccoccus bovis, Pseudomonas aeroginosa
and Streptococcus mitis respectively. One patient’s
culture dating from one day before study inclu-
sion (day –1: patient 6 (red) with Hafnia alvei) re-
turned a positive result. Cultures remained nega-
tive in two of the patients (4 (yellow) and 5 (or-
ange)), who in view of their clinical presentation
were classiﬁed as culture-negative sepsis. Sepsis
was complicated by features characterising septic
shock in three patients (patients 3–5). One of
these patients still presented severe sepsis on the
last study day (patient 5), one presented signs and
symptoms indicative of sepsis (patient 3), and one
Results
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Contact system activation in sepsis vs. controls (analysis in U/ml).
Panel A shows the six individual patients’ results over time. Panel B shows the analysis of 47kd light chain in U/ml as a func-
tion of SiRS severity.The solid line depicts the mean of all normal controls; whereas the dotted line delimits the mean ± two
standard deviations.The categories on the x-axis are normal controls (empty circles), patients without SiRS (all patients upon
inclusion in the study had at least two SiRS criteria; on subsequent days of testing some patients only presented 1 or 0 SiRS
defining criteria and therefore were categorised in the “no SiRS” group), patients with sepsis and patients with severe sepsis
(including septic shock).The insert correlates the symbols with the respective patients and time of blood draw.The empty
bars indicate the mean CSA for each category.
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Contact system activation in sepsis vs. controls (analysis in %).
Panels A and B are organised similarly to Figure 2. Panel A shows the analysis for 47kd light chain in % of total Hk. For this
analysis the sum of all three detected bands (120kd + 61kd + 47kd) was considered to equal 100%. As well as illustrating
increased CSA as a function of SiRS severity in sepsis patients, this figure shows that in healthy controls approximately
10% of Hk circulates in its cleaved form under basal conditions.This result suggests a basal turnover of Hk with a persistence
of the 47kd fragment in the circulation. See Results section for comments regarding *.
A B
A B
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shock patient no longer showed signs of SIRS by
the end of the study period (patient 4). Of the
three patients who did not have severe sepsis or
septic shock, two still classiﬁed for sepsis by day 8,
whereas patient 1 no longer presented the requi-
site criteria for that diagnosis.
Contact system activation in sepsis
The time course of contact system activation
for the six patients as deﬁned by the absolute
amount of 47kD band of HK in U/ml is depicted
in ﬁgure 2A. CSA correlates with the severity of
the underlying inﬂammatory state (ﬁgure 2B).
Using this analysis, three patients (2, 3 and 4) had
pathologically high levels of 47kD HK. One pa-
tient (5) had results below the normal range. Con-
trols are indicated for comparison. The solid line
represents the mean control value; dotted lines
represent the range of normal values.
Analysis by relative abundance of 47kD HK,
expressed as % of total HK, is depicted in ﬁgures
3A and 3B.This analysis identiﬁed the same three
patients from the above-mentioned group (pa-
tients 2, 3, 4) and a fourth patient, patient 6, who
had pathological results on days 2, 3 and 8.
The empty bars in ﬁgures 2B and 3B depict
the mean contact system activation of the
SIRS/sepsis patients. The values ranged from the
lowest values in controls (0.08 U/ml or 10.4%; as
depicted by the solid line), to patients without
SIRS (0.10 U/ml or 15.1%), to patients with SIRS
(0.12 U/ml or 15.0%), and ﬁnally to patients with
severe sepsis or septic shock (0.13 U/ml or
17.4%). There was one outlier, day 8 of patient 4
in Figure 3B: see asterix. If this outlier is excluded
from the analysis of means, the resultant mean
CSA for the “no SIRS” group in ﬁgure 3B would
be 12.1% (in contrast to 15.1%, see above).
Table 1 shows that, while HK expressed in ab-
solute terms (U/ml) did not differ in the sepsis
and control groups (0.77 vs. 0.78 U/ml of whole
blood), there was signiﬁcantly more 47kD HK
present in sepsis patients (see asterix). This holds
true both in U/ml and in % of total HK.
Other Coagulation Studies
Clotting activity for FXII, HK, PK and FXI
was assayed in all six patients on the four study
dates. Table 2 shows the standard markers of CSA
used in previous studies. The implications of
these studies are commented on in the discussion.
In our patient cohort at least one of the 4 assays
showed decreased values in each of the six pa-
tients. However, the majority of measurements
were normal or increased (60 out of 96). In con-
trast to 47kD HK, no correlation between re-
duced contact system factors (FXII, HK, PK or
FXI) and severity of SIRS was detectable.
Sepsis patients Controls
U/ml 120kD band 0.63 (0.11) 0.67 (0.08)
61kD band 0.02 (0.01) 0.02 (0.01)
47kD band 0.12 (0.03)* 0.08 (0.01)*
Total HK 0.77 (0.12) 0.78 (0.08)
% 120kD band 81.8 (3.2) 86.3 (1.0)
61kD band 2.4 (1.0) 3.3 (0.5)
47kD band 15.8 (2.3)* 10.4 (0.7)*
Total HK 100 100
Results are given as arithmetic mean
(± the value to obtain the 95% conﬁdence interval).
Table 1
Hk split products
Patient 1 (purple) Patient 2 (blue) Patient 3 (green) Patient 4 (yellow) Patient 5 (orange) Patient 6 (red)
Day 1 2 3 8 1 2 3 8 1 2 3 8 1 2 3 8 1 2 3 6 1 2 3 8
SIRS sc. 2 1 0 1 3 3 3 2 3 3 3 2 3 3 2 1 3 3 3 2 2 2 2 2
SIRS cat. S o o o SS SS SS S SS SS SS S SS SS S o SS SS SS S S S S S
FXII 60 71 65 76 86 64 66 68 81 93 100 82 61 74 80 78 48 27 27 24 20 38 45 47
PK 64 65 78 52 61 59 60 73 59 97 96 86 72 56 51 92 44 25 29 24 38 38 41 87
HK 129 87 94 91 130 118 102 114 90 101 192 129 89 103 126 154 56 54 75 50 94 102 108 103
FXI 79 56 87 79 95 62 81 67 63 87 99 95 46 64 82 107 39 28 36 44 49 81 73 76
Table 2
Standard parameters of CSA. MannWhitney rank sum test.
Abbreviations and comments: score (sc., SiRS score according to [22]), category (cat.): no SiRS (o, white) SiRS (S, light grey)), severe sepsis and/or
septic shock (SS, dark grey), clotting factor activity for FXii (normal range: 61–145%), Pk (65–120%); Hk (65–140%) and FXi (65–140%); bold characters
indicate pathological results.
Discussion
We have shown that contact activation can be
detected early in a subset of patients with sepsis.
Deﬁning CSA as an increase in the absolute con-
centration of 47kD HK (U/ml), we identiﬁed
three patients with contact system activation. The
test turned positive early on in the course of sep-
sis, namely on day 1 or 2, staying positive there-
after. If one uses the relative concentration of
47kD band (% of total HK), the same three pa-
tients were identiﬁed on day 1 or 2 as well as one
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additional patient (patient six). Three out of these
four patients remained positive for the rest of the
study period, whereas one patient’s results nor-
malised on day 3 and 8. Out of the four patients
who had a positive test in either analysis, three
had severe forms of sepsis (severe sepsis or septic
shock). Two patients did not test positive. Other
CSA parameters were negative or inconclusive in
our study patients. This suggests that our assay
identiﬁed sepsis associated with adverse outcome
in a subpopulation of patients.
Several studies have reported CSA in sepsis in
the past, with ﬁrst reports dating back to the
1970s [28–38]. The main confounding factor in
these studies was the lack of consensus on how to
deﬁne CSA. Decreased coagulation factor levels
for factor XII, prekallikrein and HK have been
proposed as measures of CSA. However, different
reports have shown these values to be increased,
normal or reduced in different sepsis patients,
making analysis difﬁcult. Tables 1 and 2 illustrate
how contact system activation may be overlooked
if one analyses only the total concentration of a
contact system protein. Previous reports [39] and
our own results support the notion that absolute
concentrations of contact system proteins at the
time of study enrolment into the relevant study
do not reliably include or rule out CSA or predict
patient outcome. Assays for activated contact fac-
tors such as FXIIa have been proposed but also
remain debatable. Complexes of coagulation fac-
tor inhibitors bound to activated coagulation fac-
tors such as C1Inh-FXIIa, C1Inh-KK, or a1-an-
titrypsin-FXIa and a2-macroglobulin-KK have
also been studied. Again, no single assay has es-
tablished itself for deﬁnition of CSA in sepsis.We
propose 47kD HK as a marker for contact system
activation in the context of sepsis. Our assay has
two advantages over other assays: i) it deﬁnes
CSA through the generation of a speciﬁc and per-
sistent product, the 47kD light chain of HK, and
ii) it indicates that an important mediator in sep-
sis, the vasoactive peptide bradykinin, has been
released (ﬁg. 1).
In our patients the degree of CSA correlated
with the severity of SIRS/sepsis. Mean (depicted
by empty bars in the ﬁgure) and median CSA (not
depicted) increased from controls to patients
without SIRS, to those with SIRS and ﬁnally to
those with severe sepsis in the 47 kD HK analysis
by U/ml (ﬁgure 2A) and in % (ﬁgure 2B) with
one exception. In the analysis of CSA in % the
mean CSA of patients without SIRS was smaller
than that of patients with SIRS (15.1 vs 15.0; the
higher average in the no SIRS group is at-
tribuable to one outlier: see asterisk). Our data are
however preliminary and based on a small patient
population. Conﬁrmation of this ﬁnding in a
larger cohort is necessary. Such conﬁrmation is of
signiﬁcant clinical interest since patients with se-
vere sepsis and septic shock have the highest mor-
tality risk.We predict that patients with high lev-
els of 47kD would beneﬁt most from treatment
whih speciﬁcally targets the contact system, such
as C1Inh. Any treatment aimed at reducing mor-
tality in sepsis should target a pathway that is ac-
tive in these patients.
Earlier studies on CSA in culture negative vs.
culture positive sepsis [30, 31] either used varying
deﬁnitions of sepsis, adopted criteria of severity
not predictive of an adverse outcome, did not de-
scribe criteria of patient recruitment, used pa-
tients from previous studies, used less sensitive
methods to detect HK cleavage and non- or less
speciﬁc markers for CSA, or described CSA only
at single time points. In this study we adopted a
deﬁnition of SIRS and sepsis that is based on a
consensus statement [22] for which the criteria of
severity have been prospectively validated [2, 40].
Moreover, we followed our patients over 4 time
points. However, our study has several limita-
tions. It is a preliminary study based on a small
patient population. The normal ranges were de-
ﬁned using 24 values, which sensu stricto were not
independent measurements. We were unable to
assay HK cleavage using an alternative method.
Disease severity at study inclusion was not
prospectively registered.
Surfaces on which contact system activation
occurs in vivo have been identiﬁed in recent years.
Such surfaces include endothelial cells [41–44],
polymorphonuclear neutrophils [45], platelets
[46, 47] and various bacteria [48–50]. It is interest-
ing that all of the above in vivo targets also play
central roles in the pathogenesis of sepsis, and
hence are sites of potential therapeutic interven-
tion. Although the site of CSA in our study is un-
deﬁned, comparative studies in whole blood,
platelet rich plasma and platelet poor plasma
demonstrated a cell bound fraction of HK (data
not shown) suggesting a role of HK bound to cir-
culating cellular elements.
To date the only coagulation-modifying drug
that has been shown to reduce sepsis-related mor-
tality in a prospective randomised study with pre-
deﬁned outcomes is activated protein C [5]. Most
trials investigating drugs which modulate the
contact system in SIRS/sepsis patients have failed
to show an improved patient outcome. Trials in
humans and animals have investigated mono-
clonal antibodies directed against FXIIa [51], di-
rect BK antagonists [52], or also inhibitors of con-
tact factors such as ATIII [6] and C1 inhibitor [9].
A meta-analysis of controlled trials of anticoagu-
lant treatments for sepsis concluded that, since
the degree of beneﬁt from the various treatment
regimens depends on disease severity, “the safety
and efﬁcacy of these agents may be enhanced by
reﬁnement in techniques of clinical stratiﬁcation”
[53]. Future studies will have to show whether our
assay represents such a reﬁnement.
In conclusion, our results show that the con-
tact system became activated early on, that the ac-
tivation was persistent in a subset of sepsis pa-
tients, and that the activation correlated with the
severity of the inﬂammatory syndrome. 47kDHK
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